Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

BACKGROUND. PALOMA‐2 confirmed that first‐line palbociclib + letrozole improved progression‐free survival (hazard ratio, 0.58; 95% confidence interval, 0.46–0.72) in postmenopausal women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Diéras, Véronique, Harbeck, Nadia, Joy, Anil Abraham, Gelmon, Karen, Ettl, Johannes, Verma, Sunil, Lu, Dongrui R., Gauthier, Eric, Schnell, Patrick, Mori, Ave, Rugo, Hope S., Finn, Richard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975938/
https://www.ncbi.nlm.nih.gov/pubmed/31217344
http://dx.doi.org/10.1634/theoncologist.2019-0019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975938/
https://www.ncbi.nlm.nih.gov/pubmed/31217344
http://dx.doi.org/10.1634/theoncologist.2019-0019

Ejemplares similares